Get the Stockscreener App
1.33
2.31%
+0.03
After Hours:
1.32
-0.01
-0.75%
Marinus Pharmaceuticals Inc stock is currently priced at $1.33, with a 24-hour trading volume of 1.30M.
It has seen a +2.31% increased in the last 24 hours and a -7.64% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.32 pivot point. If it approaches the $1.34 resistance level, significant changes may occur.
Previous Close:
$1.30
Open:
$1.31
24h Volume:
1.30M
Market Cap:
$6.49M
Revenue:
$30.99M
Net Income/Loss:
$-141.41M
P/E Ratio:
-8.8667
EPS:
-0.15
Net Cash Flow:
$-118.12M
1W Performance:
+0.00%
1M Performance:
-7.64%
6M Performance:
-78.44%
1Y Performance:
-84.00%
1D Range:
$1.30
$1.38
52W Range:
$1.11
$11.26
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Name
Marinus Pharmaceuticals Inc
Sector
Industry
Phone
484-801-4670
Address
170 North Radnor Chester Road, Suite 250, Radnor, PA
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-23 | Initiated | RBC Capital Mkts | Outperform |
| Sep-30-20 | Initiated | Truist | Buy |
| Jul-01-20 | Initiated | Cowen | Outperform |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-09-20 | Initiated | Craig Hallum | Buy |
| Dec-20-19 | Initiated | Oppenheimer | Outperform |
| Mar-05-19 | Resumed | Jefferies | Buy |
| Feb-27-19 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-19 | Initiated | Leerink Partners | Outperform |
| Jul-02-18 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-20-18 | Initiated | Mizuho | Buy |
| Feb-15-18 | Initiated | H.C. Wainwright | Buy |
| Dec-14-17 | Initiated | Laidlaw | Buy |
| Aug-10-16 | Reiterated | Jefferies | Buy |
| Jun-14-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-08-16 | Reiterated | Stifel | Buy |
| Dec-17-15 | Initiated | RBC Capital Mkts | Outperform |
| Nov-17-15 | Initiated | Jefferies | Buy |
| Oct-30-15 | Reiterated | Oppenheimer | Outperform |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
View All
Marinus Pharmaceuticals Inc Stock (MRNS) Latest News
Marinus Pharmaceuticals completes TrustTSC trial enrollment - Investing.com India
Investing.com India
Marinus Pharmaceuticals completes TrustTSC trial enrollment By Investing.com - Investing.com
Investing.com
Marinus Pharmaceuticals completes TrustTSC trial enrollment By Investing.com - Investing.com UK
Investing.com UK
Marinus Pharmaceuticals announces completion of enrollment in tuberous sclerosis complex program - MSN
MSN
Here's Why Marinus Pharmaceuticals (MRNS) is Poised for a Turnaround After Losing -7.8% in 4 Weeks - Yahoo Finance
Yahoo Finance
MSN - MSN
MSN
Marinus Pharmaceuticals Inc Stock (MRNS) Financials Data
Marinus Pharmaceuticals Inc (MRNS) Revenue 2024
MRNS reported a revenue (TTM) of $30.99 million for the quarter ending December 31, 2023, a +21.63% rise year-over-year.
Marinus Pharmaceuticals Inc (MRNS) Net Income 2024
MRNS net income (TTM) was -$141.41 million for the quarter ending December 31, 2023, a -613.59% decrease year-over-year.
Marinus Pharmaceuticals Inc (MRNS) Cash Flow 2024
MRNS recorded a free cash flow (TTM) of -$118.12 million for the quarter ending December 31, 2023, a -3.02% decrease year-over-year.
Marinus Pharmaceuticals Inc (MRNS) Earnings per Share 2024
MRNS earnings per share (TTM) was -$2.63 for the quarter ending December 31, 2023, a -484.44% decline year-over-year.
Marinus Pharmaceuticals Inc Stock (MRNS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Feb 20 '24 |
Sale |
9.56 |
2,153 |
20,583 |
60,308 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Feb 20 '24 |
Sale |
9.57 |
1,894 |
18,126 |
52,966 |
| Braunstein Scott | CHAIRMAN AND CEO |
Feb 16 '24 |
Sale |
9.94 |
11,850 |
117,789 |
223,512 |
| Pfanstiel Steven | CFO AND COO |
Feb 16 '24 |
Sale |
9.97 |
3,092 |
30,827 |
71,697 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Feb 16 '24 |
Sale |
9.98 |
2,814 |
28,084 |
66,635 |
| Braunstein Scott | CHAIRMAN AND CEO |
Aug 08 '23 |
Sale |
8.94 |
30 |
268 |
160,762 |
| Pfanstiel Steven | CFO AND COO |
Aug 08 '23 |
Sale |
8.93 |
14 |
125 |
49,324 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Aug 08 '23 |
Sale |
8.93 |
13 |
116 |
47,614 |
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Aug 08 '23 |
Sale |
8.93 |
11 |
98 |
40,626 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Aug 08 '23 |
Sale |
8.93 |
11 |
98 |
33,025 |
About Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
0.77%
1.20%
Cap:
|
Volume (24h):